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Background: Survival of locally advanced/unresectable non-small
cell lung cancer (NSCLC) has improved with the use of concurrent
radiation and chemotherapy over the past decades, but local and
distant failure remain high. In addition, a key limiting factor in
combining chemotherapy with accelerated radiotherapy (ART) is
severe esophagitis. We investigated the toxicity, response rate, and
overall survival (OS) with induction carboplatin and vinorelbine
followed by concomitant topotecan and ART in patients with locally
advanced/unresectable NSCLC.
Methods: In this phase II trial, stage IIIA or IIIB NSCLC patients
with a Karnofsky performance score 60 were eligible. Patients
received induction carboplatin (area under the curve  5.5) on days
1 and 22, and vinorelbine (25 mg/m2) on days 1, 8, 22, and 29.
During the concurrent chemoradiation, patients received intravenous
topotecan (0.5 mg/m2) on days 43 to 47, days 57 to 61, and days 71
to 75 before the morning radiotherapy (RT) fraction. RT was
administered in an accelerated fashion at 2 Gy per fraction, twice
daily for five consecutive days, every other week, to a cumulative
dose of 60 Gy during a 5-week period.
Results: Thirty-seven patients were accrued; of these, 35 were
evaluable. Overall response rate was 71% (14% complete response,
57% partial response). Six of 35 (17%) patients had stable disease.
Four (11%) patients progressed during treatment. At a median
follow-up of 45 months for surviving patients, the median survival
based on Kaplan–Meier estimates is 17.9 months. OS at 1, 2, and 3
years is 62%, 41%, and 33%, respectively. Actuarial 5-year OS is
21%. The median time to first relapse is 12.2 months (9.1–24.7
months). There were no cases of grade 3 or 4 esophagitis.
Conclusions: This combined-modality regimen yielded encourag-
ing OS rates, with no severe esophagitis. Using four-dimensional RT
treatment planning, we plan to further evaluate altered fractionation
RT and chemotherapy for this group of patients.
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Lung cancer is the leading cause of cancer-related death inmen and women in the United States, accounting for
162,460 deaths in 2006. Approximately one third of these
patients are diagnosed annually with locally advanced/unre-
sectable disease (stages IIIA and IIIB). The “gold standard”
treatment strategy has been concurrent chemotherapy with
once-daily radiation (RT) to a dose of 60 to 63 Gy.1–6
Nevertheless, this treatment fails to control disease within the
thorax in a significant portion of patients. In addition hema-
togenous metastasis remains a significant problem with the
majority of patients dying of metastatic disease. Although
concurrent chemotherapy and RT have made significant ad-
vances over sequential chemotherapy followed by RT, the
median survival is still around 17 months.3,5,6 Further inten-
sification of the RT such as via altered fractionation, has
shown some promise, but acute toxicity rates especially
esophagitis are quite high.7–9
Hyperfractionation using 1.2 Gy twice daily has been
extensively studied by the Radiation Therapy Oncology
Group (RTOG). It was concluded that a dose of 69.6 Gy was
optimal.10 This regimen resulted in a median survival and a
2-year survival rate of 10 months and 20%, respectively. The
RTOG further studied hyperfractionation in a randomized
phase II trial comparing hyperfractionated RT (69.6 Gy in 58
fractions) with cisplatin chemotherapy versus induction cis-
platin and vinblastine followed by cisplatin combined with
RT (63 Gy in 34 fractions).8 This trial showed a significant
lengthening of time to in-field progression for the concurrent
chemotherapy and hyperfractionated RT arm at the cost of
higher rates of esophagitis. Similarly, when this hyperfrac-
tionated RT plus chemotherapy regimen was studied in a
subsequent randomized trial (RTOG 94-10), this arm was
associated with the best local control, but the highest rates of
severe esophagitis (50%).11
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At our institution, accelerated RT (ART) was first
attempted in locally advanced head and neck cancer on the
basis of previous data by Wang et al., yielding dramatic
tumor responses and impressive locoregional control.12,13 The
use of accelerated RT is based on the concept that accelerated
tumor clonogen repopulation during standard radiotherapy
compromises the control rate.14 The use of accelerated radio-
therapy resulting in the reduction of the overall treatment
time may result in a therapeutic advantage.15 We elected to
use an every other week regimen of hyperfractionated, accel-
erated RT and chemotherapy in an attempt to reduce the acute
complications—namely, esophagitis—that would occur with
a continuous accelerated program, especially when combined
with chemotherapy.16 Despite the interruption, the overall RT
treatment time remained relatively short, at 5 weeks.
In 1990, we developed a phase II trial examining a
treatment regimen for locally advanced (stages IIIA and IIIB)
carcinoma of the lung that used ART therapy consisting of
55.6 Gy in 30 fractions (1.8 Gy bid for five consecutive days,
given every other week).17 Concurrent chemotherapy in-
cluded cisplatin (10 mg/m2), vinblastine (4 mg/m2), 6-thio-
guanine (40 mg, twice daily), and 5-fluorouracil (400 mg/m2,
continuous infusion), and consolidation chemotherapy con-
sisted of two cycles of cisplatin (120 mg/m2) and vinblastine
(4 mg/m2). The trial showed promising results: a 63% re-
sponse rate, with a median survival of 17.5 months. Further-
more, the acute grade 3 or 4 esophagitis rate was only 2.8%.
Because of the poor tolerance to consolidation chemotherapy,
we elected to deliver two cycles of chemotherapy upfront in
this trial. We also decided to use cisplatin and vinorelbine as
induction chemotherapy because of data suggesting improved
activity of cisplatin and vinorelbine over cisplatin alone.18
Because of the low toxicity encountered in the first trial, we
elected to increase the dose per fraction to 2.0 Gy, giving a
total dose of 60 Gy in 5 weeks. For the chemotherapy used
during the ART portion of the treatment, we chose to use
topotecan concurrently. The decision to add topotecan to this
regimen was the result of data generated in our laboratory
indicating that this drug has significant RT-enhancing prop-
erties.19 In our preclinical studies, topotecan caused a dose-
dependent reduction in cell survival after irradiation in Hela
S-3 cells and in murine fibrosarcoma. Moreover, phase I and
II trials have shown efficacy in the treatment of non-small cell
lung cancer (NSCLC).20,21 A phase I trial has shown that the
optimal dose of 0.5 mg/m2 during thoracic irradiation can be
safely delivered, while avoiding hematologic and gastrointes-
tinal toxicity.21 Because of the promising results of our
previous phase II trial, we decided to study the use of ART in
conjunction with novel chemotherapeutic agents to further
improve efficacy while minimizing toxicity in locally ad-
vanced NSCLC patients.
PATIENTS AND METHODS
Patient Eligibility and Statistics
This was a phase II trial with a two-stage clinical design
with a planned sample size of 40 patients and an expected
response rate of 85%, representing an absolute improvement
of 20% over our previous phase II trial.17 Initially, 20 patients
were enrolled, and a planned interim analysis revealed 17
patients achieving objective responses, which required an-
other 20 patients to be enrolled to the second stage. On a
second interim analysis, 10 of the 37 patients failed to
achieve objective responses and because the study goal re-
sponse rate could not be met, an early-stopping rule required
the trial to be stopped early. Therefore, between June 1999
and December 2003, 37 patients with locally advanced,
unresectable NSCLC were enrolled on an institutional review
board approved protocol using induction chemotherapy fol-
lowed by combined chemotherapy and ART. Eligibility re-
quirements included having histologically or cytologically
proven NSCLC with unresectable stage IIIA or IIIB disease
as demonstrated on computed tomography (CT) scan of the
chest and upper abdomen. In addition, a 24-hour creatinine
clearance of 60 ml/min or greater, white blood count equal to
4000 or greater, and a platelet count greater than 100,000
were required. Patients were required to be 18 years of age,
capable and willing to sign an informed consent form, and
have a Karnofsky performance score (KPS)  60. Patients
with prior diagnosis of a second malignancy, except for basal
cell carcinoma of the skin, were ineligible. Moreover, those
previously treated with RT or chemotherapy were ineligible.
Before registration, a pretreatment evaluation was done
consisting of a complete history and physical, complete blood
count, differential, and platelet count, 24-hour urine for
creatinine clearance or a calculated creatinine clearance and
screening profile of liver function and serum electrolytes.
Radiologic imaging included CT scan of the chest and upper
abdomen. A CT scan of the brain if neurologic abnormalities
were present on history or on careful neurologic exam, and
radionuclide scans of the bone were done if clinically indi-
cated. Bronchoscopy was performed in the majority of cases,
but this was not required.
Of the 37 patients enrolled, 35 patients were evaluable.
One patient completed the induction phase of the protocol but
was taken off the protocol because of persistent thrombocy-
topenia. A second patient completed the planned treatment
course but was lost to follow-up. The patient characteristics
are listed in Table 1.
Treatment Program
The induction phase of treatment consisted of carbo-
platin (area under the curve  5.5) on days 1 and 22,
administered by intravenous infusion for 30 minutes, and
vinorelbine (25 mg/m2) on days 1, 8, 22, and 29, administered
by intravenous infusion for 5 to 10 minutes. Dose adjust-
ments were based on blood counts, renal function, hepatic
function, and/or neurologic toxicity. The combined chemo-
therapy–RT phase began on day 43. ART was delivered at 2
Gy per fraction, twice a day, for a total dose of 60 Gy on days
43 to 47, days 57 to 61, and days 71 to 75, including two
planned breaks during weeks 8 and 10. Each day, the treat-
ment fractions were separated by at least 6 hours. Topotecan
(0.5 mg/m2, administered intravenously for 30 to 60 minutes)
was administered 1 to 2 hours before the first RT treatment
daily on days 43 to 47, days 57 to 61, and days 71 to 75.
RT was planned using a CT simulation with patients in
the supine position. An alpha cradle or approved alternate
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immobilization was required. Intravenous contrast during the
planning CT was optional, provided a diagnostic chest CT
with contrast was done. Three-dimensional conformal RT
was used with megavoltage equipment with photon energies
6 MeV required. Secondary blocking was used in all cases
with cerrobend blocks or multileaf collimation. The initial
treatment volume was a clinical target volume (CTV) con-
sisting of the gross tumor volume (GTV)  1.5 to 2 cm to
encompass primary echelon lymph nodes. Furthermore the
GTV included abnormally enlarged lymph nodes measuring
1.0 cm in the short axis. The initial planning target volume
provided a minimum margin of 1.0 cm around the CTV, with
an additional margin if deemed necessary for respiratory
motion, as measured by fluoroscopy. This initial PTV was
treated to a minimum dose of 44 Gy at 2 Gy per fraction. This
was followed by a boost of 16 Gy at 2 Gy per fraction to the
GTV. The initial field was treated twice a day (morning and
afternoon/evening) during weeks 7 and 9 and on the first day
of week 11. On the remaining 4 days of week 11, the boost
volume was treated in the morning and afternoon/evening.
Maximum doses to critical normal tissues were 25 Gy to
peripheral lung not within target volume, 42 Gy to the spinal
cord, 45 Gy (if feasible) to the esophagus, and 35 Gy to
50% of the heart.
Treatment Evaluation
Four to six weeks after completion of treatment, pa-
tients underwent CT scanning of the chest and upper abdo-
men to evaluate their responses, using the World Health
Organization response criteria, which was the primary end-
point. Partial response was defined as greater than 50%
decrease in the product of the longest perpendicular diameters
of each measurable lesion. Complete response was defined as
the absence of clinical, laboratory, and radiographic evidence
of disease. The definition of progression of disease includes
the appearance of new lesions or the increase of measurable
disease. Follow-up visits were conducted every 3 months for
the first 2 years, then every 6 months thereafter. Before each
follow-up visit, a CT scan of the chest and upper abdomen
was obtained. Acute and late toxicity were scored using the
RTOG/European Organisation for Research and Treatment of
Cancer toxicity criteria. Survival was calculated from the
time of registration on the study until death, using the
Kaplan–Meier actuarial method.
RESULTS
Toxicity
The most common acute toxicity was hematologic,
with grade 3 or 4 leukopenia occurring in 74% of patients and
grade 3 or 4 anemia occurring in 17% of patients. The
majority of patients experienced hematologic toxicity during
the induction phase of the treatment. This resulted in 20% of
patients receiving a delay or reduction in dose of chemother-
apy. The hematologic toxicity was reversible in the vast
majority of patients, such that no patient had the two cycles
of induction chemotherapy omitted, and only one patient
received one of the two cycles of induction chemotherapy.
Five patients experienced an infectious process, which in-
cluded postobstructive pneumonia, bacterial sepsis, perianal
fungal infection, and mediport infection. The most common
acute toxicity during the concurrent topotecan and ART was
esophagitis. All cases of esophagitis were grade 1 or 2, which
occurred in 19 (54%) patients. All 35 evaluable patients were
able to complete the concurrent phase of treatment without
any interruptions. One patient did not receive the boost-RT
portion because of the diagnosis of metastatic brain disease.
The most common late toxicity was cough, which was
all grade 1 or 2, and occurred in 11 (31%) patients. Two
patients were diagnosed with grade 3 or 4 pneumonitis; the
patient with grade 4 pneumonitis was also diagnosed with a
pulmonary embolus. No unusual late toxicities were noted.
Table 2 summarizes the acute and late toxicities.
Response/Survival
A total of 25 (71%) patients had a partial or complete
response to the therapy (Table 3). Of the five patients who
had a complete response, only two patients lived longer than
one year. Furthermore, it was interesting to note that two of
the nine patients living longer than 3 years were deemed
nonresponders and that five of the nine patients were partial
TABLE 1. Patient Characteristics
Number Percent
Age
60 6 17
60 29 83
Gender
Male 23 66
Female 12 34
Weight loss percentage
5 28 80
5–10 3 9
10 4 11
KPS
60–70 7 20
80–100 28 80
Type
Squamous 12 34
Adenocarcinoma 11 32
Non-small cell 12 34
AJCC stage
IIIA 25 74
IIIB 10 26
AJCC TNM
T1N2 8 23
T2N2 12 34
T3N2 5 14
T4N0 2 6
T4N2 5 14
T2N3 1 3
T3N3 1 3
TxN3 1 3
KPS, Karnofsky performance status; AJCC, American Joint Committee on Cancer;
TNM, tumor, node, metastasis.
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responders. No association was found between treatment
response and survival beyond 3 years (p  0.92). The
Kaplan–Meier 1-year, 2-year, 3-year, and actuarial 5-year
overall survival (OS) were 63%, 40%, 30%, and 17%, re-
spectively, as shown in Figure 1. The median OS was 17.9
months (95% confidence interval: 10–30.7 months), with a
median follow-up of 45 months. Five patients lived longer
than 4.5 years, with four of these long-term survivors still
alive at this time. A total of seven baseline covariates,
including stage (IIIA versus IIIB), tumor histology, age,
gender, Karnofsky score, the maximum lesion size greater
than the observed median (5.3 cm) and weight loss 5%,
were included in the analysis. Results showed that the lesion
size had a trend towards predicting (p  0.10) survival on
univariate analysis. On multivariate analysis, the one variable
retained was maximum lesion size (p  0.009). Patients with
a maximum lesion size 5.3 cm had a fourfold risk (hazards
ratio  4.43; confidence interval  1.84–10.64) of death.
Figure 2 shows the Kaplan–Meier curve stratified for lesion
size.
Patterns of Failure
The median time to first relapse was 12.2 months
(9.1–24.7 months). Some type of failure was seen in 24 of the
35 patients (69%), with the most common first relapse being
local failure. Patients living longer than 3 years did not show
a specific pattern of failure: three patients failed locally, one
patient failed distantly, two patients failed locally and dis-
tantly, and three patients had stable disease. Table 4 summa-
rizes the patterns of failure.
DISCUSSION
This trial was designed to build on the previous trial we
had performed in the phase II setting.17 The prior trial
consisted of 35 patients and used ART to a total dose of 55.6
Gy at 1.8 Gy, twice a day. Patients received concurrent
chemotherapy consisting of cisplatin, vinblastine, 6-thiogua-
nine, and 5-flurouracil, and then consolidation chemotherapy
consisting of cisplatin and vinblastine. Because of the poor
compliance and tolerance to the consolidation chemotherapy,
our current trial implemented two cycles of chemotherapy
upfront. Our current trial was able to deliver the induction
chemotherapy with good compliance and minimal dose re-
ductions, and it also achieved an escalation in the RT dose
without increasing the toxicity rates. Compared with the
previous trial, the overall response rate was 71% versus 63%.
Furthermore, the median survival was similar at 17.9 months
versus 17.5 months, though the 3-year survival was higher at
30% versus 20% in the previous trial. Similar toxicity profiles
were noted, with minimal grade 3 or 4 esophagitis seen.
Interestingly, our previous trial had an increased distant
failure rate of 40% compared with our current trial rate of
23%, which may have been attributable to the poor tolerance
to consolidation chemotherapy in the prior trial.
One of the major problems associated with the use of
altered fractionation with chemotherapy is severe esophagitis.
It has been shown, in an analysis of predictors for esophagitis
by Werner-Wasik et al.,9 that the maximum acute esophagitis
grade is associated with the use of chemotherapy and twice-
daily RT. Many trials using concurrent chemotherapy with
altered fractionation have shown increased grade 3 and 4
TABLE 2. Toxicity
Grade 1 Grade 2 Grade 3 Grade 4 Grade 3/4 (%)
Acute
Anemia 9 15 8 1 17
Leukopenia 5 5 14 12 74
Thrombocytopenia 11 4 2 0 6
Esophagitis 13 6 0 0 0
Mucosal 1 0 0 0 0
Nausea/vomiting 12 3 2 0 6
Cough 12 3 0 0 0
Infection 0 4 1 0 3
Renal 0 0 0 0 0
Hearing loss 0 1 1 0 3
Late
Dyspnea 1 2 1 0 3
Cough 8 3 0 0 0
Radiation pneumonitis 0 2 1 1 6
Hearing 0 0 0 0 0
Renal 0 0 0 0 0
Esophagus 1 1 0 0 0
TABLE 3. Response
Response Number Percent
Complete response 5 14
Partial response 20 57
No response 6 17
Progression 4 11
Any response 25 71
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esophagitis rates 30%6,8,16 Yet, our regimen of ART al-
lowed us to deliver 60 Gy in 5 weeks, with essentially no
severe esophagitis.
At the same time, regarding survival, our median sur-
vival of 17.9 months was comparable with the median sur-
vival of 17.0 months reported for the concurrent chemother-
apy and once-daily RT arm in RTOG 94-10 and the median
survival of 16.5 months reported for the concurrent chemo-
therapy and RT arm in the Japanese randomized trial.5,6 The
5-year survival rate was similarly promising, at 20%. Of note,
FIGURE 1. Overall survival.
FIGURE 2. The effect of lesion size (5.3 cm in black versus 5.3 in red) on survival.
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the Japanese trial included a planned 2-week treatment break,
whereas our trial used two 1-week breaks. Although treat-
ment breaks are not considered optimal because of the pos-
sibility of accelerated repopulation, it is critical to keep in
mind that our regimen delivered 60 Gy in only 5 weeks. From
a radiobiological perspective, this is a more intensive RT
dose than 60 to 63 Gy in 6 to 7 weeks (using once-daily RT).
On multivariate analysis, it was not surprising to find
that lesion size had a significant effect on survival, because
this factor reflects tumor volume. Local failure was a com-
ponent of initial treatment failure in 16 patients (46%),
indicating a need for more effective locoregional control. We
feel that treatment intensification should include escalating
the dose of RT. One possibility is to continue ART to a dose
above 60 Gy, because we were able to minimize our dose-
limiting toxicities. A recent phase I dose-escalation study
reported by Marks et al.22 used induction carboplatin/pacli-
taxel or carboplatin/vinorelbine and then accelerated hyper-
fractionated conformal RT alone; in that study, well-selected
patients were able to tolerate a dose of approximately 80 Gy
using 1.25 to 1.6 Gy, twice daily. RTOG is currently devel-
oping an RT dose-escalation trial in stage III NSCLC, com-
paring 60 Gy with concurrent chemotherapy against 74 Gy
with concurrent chemotherapy. Another option for RT dose
intensification may be stereotactic radiotherapy. There is
emerging evidence for excellent local control of early-stage
inoperable lung cancers.23,24 A fractionated stereotactic RT
boost may be useful for dose escalation while limiting the
dose to neighboring organs at risk.25 This could potentially be
targeted at areas of bulky disease during the planned ART
breaks, thereby avoiding the potential concern regarding
accelerated repopulation. Clearly, the optimal stereotactic
dose-fractionation scheme needs to be carefully studied for
central lesions, to avoid undue late toxicity.26 We have
experienced treating central lesions with stereotactic RT (us-
ing four doses up to 12 Gy) with no evidence of toxicity, with
a median follow-up approaching 1 year (Munther Ajlouni,
personal communication, 2007). With further intensification,
a dosimetric analysis of the esophagus and lung would yield
valuable information regarding the role of ART.
Our current trial does not show a marked improvement
in response over our previous trial, but both trials have shown
minimal grade III/IV esophagitis while maintaining a re-
sponse and survival rate consistent with the current literature,
as mentioned. Two variables, ART and topotecan, are respon-
sible for these findings, but it is unclear whether these
findings are secondary to ART alone, topotecan alone, or a
combination of both. The common denominator in both of
our phase II trials is the use of ART, and we feel that this RT
scheme is mainly responsible for the observed esophagitis
rates. Limited phase I data have shown grade 3 esophagitis
occurring in one of six patients treated with topotecan and
conventional external-beam RT (60 Gy at 2 Gy per day).21
Although topotecan has shown modest activity in advanced
NSCLC, and our laboratory data suggest a significant RT-
enhancing effect, more clinical data are needed regarding its
efficacy in the locally advanced NSCLC setting.27,28 Newer
agents are being evaluated to further improve the results. One
example is the use of RSR13 in a phase II trial, reported by
Choy et al.,29 using induction carboplatin and paclitaxel and
then RT (64 Gy in 32 fractions) with RSR13. They report a
median survival of 20.6 months. Studies are now emerging
testing the role of novel biologic strategies, such as tyrosine
kinase inhibitors, as part of the multimodality treatment of
patients with stage III NSCLC (e.g., the RTOG phase II study
with cetuximab30).
Although the number of patients in this prospective
phase II trial is relatively small, we are encouraged by the
promising survival rates observed, particularly in the absence
of severe esophagitis in both of our phase II trials employing
ART with chemotherapy. These experiences suggest that
ART warrants further study with treatment intensification
consisting of RT dose escalation in conjunction with novel
systemic agents.
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